Raymond James Financial Services Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-8,224	Closed	-$1.04M	–	3393
2023 Q4	$1.04M	Sell	8,224 -6,766	-45%	-$675K	﹤0.01%	1963
2023 Q3	$1.4M	Buy	14,990 +5,229	+54%	+$489K	﹤0.01%	1720
2023 Q2	$871K	Buy	9,761 +1,593	+20%	+$139K	﹤0.01%	2006
2023 Q1	$876K	Buy	8,168 +2,701	+49%	+$309K	﹤0.01%	1994
2022 Q4	$668K	Buy	+5,467	New	+$635K	﹤0.01%	2102

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Raymond James Financial Services Advisors's ASND Position: Q1 2024 in Review

Raymond James Financial Services Advisors sold out of Ascendis Pharma A/S (ASND) in Q1 2024, closing a stake of 8,224 shares — an estimated $1.04M sold.

Raymond James Financial Services Advisors first reported a position in ASND in Q4 2022 and held it in 5 quarters. The position peaked at $1.4M in Q3 2023. 189 funds tracked by Wall St. Rank hold ASND as of Q1 2024.

Raymond James Financial Services Advisors reported no remaining Ascendis Pharma A/S position as of Q1 2024 after selling out during the quarter.
Raymond James Financial Services Advisors sold 8,224 Ascendis Pharma A/S shares in Q1 2024, an estimated $1.04M.
Raymond James Financial Services Advisors first reported a position in Ascendis Pharma A/S in Q4 2022 and held it in 5 quarters.
Raymond James Financial Services Advisors's Ascendis Pharma A/S position peaked at $1.4M in Q3 2023.
189 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2024, filed 22 Apr 2024.